Scott Caudle, MD
Surgery · Elizabethton, TNNPI 1770570772
Payments from drug & device makers
Across 223 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$928
- Sunovion Pharmaceuticals Inc.$634
- Takeda Pharmaceuticals U.S.A., Inc.$306
- Revance Therapeutics, Inc.$251
- AstraZeneca$227
- Novo Nordisk$203
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,825100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $928 |
| Sunovion Pharmaceuticals Inc. | 38 | $634 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $306 |
| Revance Therapeutics, Inc. | 8 | $251 |
| AstraZeneca | 14 | $227 |
| Novo Nordisk | 13 | $203 |
| Axsome Therapeutics, Inc. | 7 | $184 |
| Lilly USA, LLC | 11 | $166 |
| Boehringer Ingelheim | 8 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $110 |
| Merz North America, Inc. | 2 | $85 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Scilex Pharmaceuticals Inc. | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 5 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $57 |
| Novartis | 3 | $46 |
| Clarus Therapeutics Inc. | 2 | $34 |
| GSK | 2 | $25 |
| Merck | 2 | $25 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $23 |
| Medtronic | 1 | $23 |
| Braeburn Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Kerecis Limited | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $8 |
How this compares
$3,825 in reported general payments places this provider in the 60th percentile of 516 surgery providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $191,671 |
| Humira(Cf) PenAdalimumab | 17 | $177,244 |
| LinzessLinaclotide | 128 | $91,299 |
| VraylarCariprazine Hcl | 58 | $88,061 |
| RexultiBrexpiprazole | 58 | $87,011 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $79,394 |
| TrulicityDulaglutide | 65 | $66,422 |
| MounjaroTirzepatide | 41 | $50,432 |
| EntrestoSacubitril/Valsartan | 43 | $39,739 |
| EliquisApixaban | 39 | $33,234 |
| RybelsusSemaglutide | 18 | $31,548 |
| Spiriva RespimatTiotropium Bromide | 46 | $31,040 |
| JardianceEmpagliflozin | 32 | $27,063 |
| AptiomEslicarbazepine Acetate | 16 | $21,654 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $21,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $203 | $223,219190 claims |
| AbbVieLinzess, Vraylar, Ubrelvy, Creon | $928 | $207,539215 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $166 | $123,574133 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $25 | $96,592112 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $77 | $87,01158 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance, Stiolto Respimat, Combivent Respimat | $142 | $77,388111 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga, Brilinta | $227 | $48,59676 claims |
| NovartisEntresto | $46 | $39,73943 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $634 | $21,65416 claims |
| Axsome Therapeutics, Inc.Auvelity | $184 | $19,97017 claims |
| Sanofi-aventis U.S. LLCLantus | $82 | $3,64238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 516 surgery providers in Tennessee.
Other surgery in Elizabethton
- Evelio RodriguezNashville$2.5M
- Heath BroussardJackson$688K
- Eric WallaceCookeville$529K
- Guy VoellerMemphis$434K
- John RobertsonJohnson City$432K
- Jaime Ponce-PortugalChattanooga$412K
- Robert MaxwellChattanooga$393K
- Mathew NinanNashville$298K
- Richard PierceNashville$276K
- Joseph BroucekNashville$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.